Business
Eupraxia Pharmaceuticals Announces Pricing of US$55 Million Public Offering of Common Shares and Pre-Funded Warrants
VICTORIA, British Columbia, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. (“Eupraxia” or the “Company”) (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology designed to optimize local, controlled drug delivery for applications with significant unmet need, today announced the pricing of its previously announced public offering (the "Offering") of 6,428,574 common shares of the Company (the “Common Shares") at a price
About this update from Eupraxia Pharmaceuticals, Inc.
[{"type":"image","alt":"Eupraxia Pharmaceuticals Inc.","displaySize":"","headline":null,"caption":"Eupraxia Pharmaceuticals Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":123,"url":"https://media.zenfs.com/en/globenewswire.com/0ccefa406788f5f477db81bee8b3678b"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/yASLZxJ58EV1_UWBsu0OKA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE3MjtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/0ccefa406788f5f477db81bee8b3678b","width":300,"height":123}},"lazy":false},{"type":"text","content":"VICTORIA, British Columbia, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. (“Eupraxia” or the “Company”) (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology designed to optimize local, controlled drug delivery for applications with significant unmet need, today announced the pricing of its previously announced public offering (the "Offering") of 6,428,574 common shares of the Company (the “Common Shares") at a price to the public of US$7.00 per Common Share and pre-funded warrants to purchase up to 1,428,571 Common Shares in lieu thereof (the “Pre-Funded Warrants”) at a price of US$6.99999 per Pre-Funded Warrant, which equals the public offering price per Common Share less the C$0.00001 per share exercise price of each Pre-Funded Warrant, for gross proceeds of approximately US$55 million, before deducting the underwriting commissions and estimated expenses incurred in connection with the Offering. Each pre-funded warrant will entitle the holder thereof to acquire one common share of the Company (a “Pre-Funded Warrant Share”) at a nominal exercise price of C$0.00001 per Pre-Funded Warrant Share and will not expire until exercised in full. In addition, the Company has granted the underwriters a 30-day option to purchase up to an additional 1,178,571 Common Shares on the same terms and conditions. All of the Common Shares and Pre-Funded Warrants in the Offering are being sold by the Company. The Offering is expected to close on February 20, 2026, subject to the satisfaction of customary closing conditions, including the listing of the Common Shares and Pre-Funded Warrant Shares to be issued under the Offering on the Toronto Stock Exchange (the “TSX”) and the Nasdaq Capital Market (the “Nasdaq”), an...